PMID- 27249660
OWN - NLM
STAT- MEDLINE
DCOM- 20170915
LR  - 20221207
IS  - 1744-8042 (Electronic)
IS  - 1462-2416 (Linking)
VI  - 17
IP  - 8
DP  - 2016 Jun
TI  - Clinical and genetic predictors of dipeptidyl peptidase-4 inhibitor treatment 
      response in Type 2 diabetes mellitus.
PG  - 867-81
LID - 10.2217/pgs-2016-0010 [doi]
AB  - AIM: To determine the clinical and genetic predictors of the dipeptidyl 
      peptidase-4 (DPP-4) inhibitor treatment response in Type 2 diabetes mellitus 
      (T2DM) patients. PATIENTS & METHODS: DPP4, WFS1 and KCNJ11 gene polymorphisms 
      were genotyped in a cohort study of 662 T2DM patients treated with DPP-4 
      inhibitors sitagliptin, vildagliptin or linagliptin. Genotyping was performed by 
      Applied Biosystems TaqMan SNP genotyping assay. RESULTS: Patients with 
      triglyceride levels less than 1.7 mmol/l (odds ratio [OR]: 2.2.; 95% CI: 
      1.031-4.723), diastolic blood pressure (DBP) less than 90 mmHg (OR: 1.7; 95% CI: 
      1.009-2.892) and KCNJ11 rs2285676 (genotype CC) (OR: 2.0; 95% CI: 1.025-3.767) 
      were more likely to response to DPP-4 inhibitor treatment compared with other 
      patients, as measured by HbA1c levels. CONCLUSION: Triglycerides, DBP and KCNJ11 
      rs2285676 are predictors of the DPP-4 inhibitor treatment response in T2DM 
      patients.
FAU - Jamaluddin, Jazlina Liza
AU  - Jamaluddin JL
AD  - Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala 
      Lumpur, Malaysia.
FAU - Huri, Hasniza Zaman
AU  - Huri HZ
AD  - Department of Pharmacy, Faculty of Medicine, University of Malaya, 50603 Kuala 
      Lumpur, Malaysia.
AD  - Clinical Investigation Centre, 13th Floor Main Tower, University Malaya Medical 
      Centre, 59100 Lembah Pantai, Kuala Lumpur, Malaysia.
FAU - Vethakkan, Shireene Ratna
AU  - Vethakkan SR
AD  - Endocrinology Unit, Department of Medicine, Faculty of Medicine, University of 
      Malaya, 50603 Kuala Lumpur, Malaysia.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160601
PL  - England
TA  - Pharmacogenomics
JT  - Pharmacogenomics
JID - 100897350
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Kir6.2 channel)
RN  - 0 (Potassium Channels, Inwardly Rectifying)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/genetics
MH  - Diastole
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Genotype
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Potassium Channels, Inwardly Rectifying/genetics
MH  - Triglycerides/blood
OTO - NOTNLM
OT  - DPP4
OT  - HbA1c
OT  - KCNJ11
OT  - Type 2 diabetes mellitus
OT  - WFS1
OT  - dipeptidyl peptidase-4 inhibitors
EDAT- 2016/06/02 06:00
MHDA- 2017/09/16 06:00
CRDT- 2016/06/02 06:00
PHST- 2016/06/02 06:00 [entrez]
PHST- 2016/06/02 06:00 [pubmed]
PHST- 2017/09/16 06:00 [medline]
AID - 10.2217/pgs-2016-0010 [doi]
PST - ppublish
SO  - Pharmacogenomics. 2016 Jun;17(8):867-81. doi: 10.2217/pgs-2016-0010. Epub 2016 
      Jun 1.